AU2007297754B2 - Heterocyclic inhibitors of c-MET and uses thereof - Google Patents

Heterocyclic inhibitors of c-MET and uses thereof Download PDF

Info

Publication number
AU2007297754B2
AU2007297754B2 AU2007297754A AU2007297754A AU2007297754B2 AU 2007297754 B2 AU2007297754 B2 AU 2007297754B2 AU 2007297754 A AU2007297754 A AU 2007297754A AU 2007297754 A AU2007297754 A AU 2007297754A AU 2007297754 B2 AU2007297754 B2 AU 2007297754B2
Authority
AU
Australia
Prior art keywords
aliphatic
optionally substituted
ring
pct
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007297754A
Other languages
English (en)
Other versions
AU2007297754A1 (en
Inventor
Alexander Aronov
Jon Come
John Court
David Deininger
David Lauffer
Pan Li
Kira Mcginty
Suganthini Nanthakumar
Dean Stamos
Kirk Tanner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2007297754A1 publication Critical patent/AU2007297754A1/en
Application granted granted Critical
Publication of AU2007297754B2 publication Critical patent/AU2007297754B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007297754A 2006-09-18 2007-09-18 Heterocyclic inhibitors of c-MET and uses thereof Ceased AU2007297754B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84535606P 2006-09-18 2006-09-18
US60/845,356 2006-09-18
PCT/US2007/020222 WO2008036272A1 (en) 2006-09-18 2007-09-18 HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2007297754A1 AU2007297754A1 (en) 2008-03-27
AU2007297754B2 true AU2007297754B2 (en) 2012-05-17

Family

ID=39092942

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007297754A Ceased AU2007297754B2 (en) 2006-09-18 2007-09-18 Heterocyclic inhibitors of c-MET and uses thereof

Country Status (9)

Country Link
US (1) US8481538B2 (enExample)
EP (1) EP2066676A1 (enExample)
JP (1) JP2010519174A (enExample)
CN (1) CN101796056A (enExample)
AU (1) AU2007297754B2 (enExample)
CA (1) CA2663528A1 (enExample)
MX (1) MX2009002842A (enExample)
NZ (1) NZ575548A (enExample)
WO (1) WO2008036272A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX393622B (es) * 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
EP2438041A4 (en) * 2009-06-01 2012-11-21 Merck Sharp & Dohme PYRAZINE-carboxamide-orexin receptor Antagonist
SI3511330T1 (sl) 2009-12-31 2021-01-29 Hutchison Medipharma Limited Sintetična umetna spojina uporabna v pripravi triazolopiridinskih zaviralcev c-Met
AU2011254242B2 (en) 2010-05-17 2015-10-29 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3H-imidazo[4,5-b]pyridine and 3,5- disubstitued -3H-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
TW201613919A (en) * 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
HRP20211864T1 (hr) 2015-07-06 2022-03-04 Alkermes, Inc. Inhibitori hetero-halo histonske deacetilaze
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
KR102526032B1 (ko) 2017-01-11 2023-04-25 로딘 테라퓨틱스, 인크. 히스톤 데아세틸라제의 바이시클릭 억제제
SI3664802T1 (sl) 2017-08-07 2022-10-28 Alkermes, Inc. Biciklični zaviralci histon deacetilaze
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
TR202010296A1 (tr) * 2020-06-30 2022-01-21 Anadolu Ueniversitesi Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244613T3 (es) * 2000-04-27 2005-12-16 Astellas Pharma Inc. Derivados de imidazopiridina.
CA2510534C (en) * 2002-12-18 2011-09-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2008060578A2 (en) * 2006-11-15 2008-05-22 Cytovia, Inc. 3-aryl-6-aryl-[1,2,4] triazolo[3,4-b][1,3,4] thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
AU2008276611A1 (en) * 2007-07-13 2009-01-22 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
KR20100114514A (ko) * 2008-02-05 2010-10-25 사노피-아벤티스 Ｐａｒ１ 억제제로서의 트리아졸로피리다진, 이의 제조방법 및 약제로서의 용도
JP2012521354A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof

Also Published As

Publication number Publication date
CN101796056A (zh) 2010-08-04
NZ575548A (en) 2011-09-30
EP2066676A1 (en) 2009-06-10
CA2663528A1 (en) 2008-03-27
AU2007297754A1 (en) 2008-03-27
US20100144739A1 (en) 2010-06-10
JP2010519174A (ja) 2010-06-03
US8481538B2 (en) 2013-07-09
WO2008036272A1 (en) 2008-03-27
MX2009002842A (es) 2009-05-27

Similar Documents

Publication Publication Date Title
AU2007297754B2 (en) Heterocyclic inhibitors of c-MET and uses thereof
AU2006320580B2 (en) Inhibitors of c-Met and uses thereof
US8937064B2 (en) Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors
NZ575346A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
WO2007117494A1 (en) Deazapurines useful as inhibitors of janus kinases
AU2009281822A1 (en) cMET inhibitors
AU2010250055A1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
KR20110039278A (ko) 단백질 키나제 억제제
EP2032562A2 (en) Selective inhibitors of rock protein kinase and uses thereof
CA2681516A1 (en) Compounds useful as inhibitors of janus kinases
AU2010258903A1 (en) Inhibitors of phosphatidylinositol 3-kinase
US20110135603A1 (en) Inhibitors of phosphatidylinositol 3-kinase
AU2010216219A1 (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
HK1146825A (en) Heterocyclic inhibitors of c-met and uses thereof
HK1161230A (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired